Navigation Links
NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
Date:6/14/2009

WHAT: Most vaccines that protect against viruses generate infection-fighting proteins called antibodies that either block infection or help eliminate the virus before it can cause disease. Attempts to create a vaccine that induces antibodies that prevent HIV infection or disease, however, have so far been unsuccessful. But several recent studies suggest promising new research directions for the development of an antibody-based HIV vaccine, according to John R. Mascola, M.D., deputy director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, and colleagues.

These studies demonstrate that, contrary to widespread belief, it is not uncommon for people infected with HIV to naturally make antibodies that can neutralize a variety of HIV strains. These antibodies do not protect people from the virus because they arise years after HIV infection is established. However, if a vaccine could prime the body to make these broadly neutralizing antibodies before exposure to HIV, they could potentially prevent infection or hold the virus at bay until an army of immune cells assembles to limit viral replication.

Based on these findings, Dr. Mascola and colleagues recommend a research strategy that uses naturally occurring, broadly neutralizing anti-HIV antibodies for the ultimate design of an antibody-based HIV vaccine.

Key aspects of this strategy include

  • Obtaining new broadly neutralizing antibodies to HIV to expand the pool available for scientists to study
  • Identifying regions on the surface of HIV that are vulnerable to broadly neutralizing antibodies and determining the atomic-level crystal structure of those regions
  • Understanding how broadly neutralizing antibodies to HIV evolve and persist
  • Clarifying the structural differences between anti-HIV antibodies that do and do not have neutralizing properties
  • Determining what quantity of broadly neutralizing antibodies an HIV vaccine must elicit to be effective
  • Learning how anti-HIV neutralizing antibodies and HIV surface proteins evolve in response to one another in people who eventually produce a powerful neutralizing antibody response to the virus
  • Clarifying how HIV surface proteins are presented to the immune cells that produce broadly neutralizing antibodies to HIV
  • Determining what immune-system conditions promote the production of broadly neutralizing anti-HIV antibodies


'/>"/>

Contact: Laura Sivitz
sivitzl@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases
2. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
3. NIAID honors AIDS activist Martin Delaney
4. NIAID media availability: Seizures following parasitic infection associated with brain swelling
5. NIAID awards contracts to search for protein markers of disease
6. NIAID creates HIV vaccine discovery branch
7. NIAID to advance B-cell approach to HIV vaccines
8. NIAID describes research priorities to fight drug-resistant tuberculosis
9. NIAID to convene HIV Vaccine Summit
10. NIAID scientists identify new cellular receptor for HIV
11. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 19, 2017 , ... Big Barker , a Philadelphia-based ... 2016 donation of dog beds to the K9 officers of the Allentown, Pennsylvania ... its contribution from city and state officials. , The U.S. House of ...
(Date:9/19/2017)... Montclair, NJ (PRWEB) , ... September 19, 2017 ... ... fall following the success of the annual PAINWeek National Conference. On October 7, ... will be an educational and exciting program providing busy clinicians and allied healthcare ...
(Date:9/19/2017)... ... 2017 , ... Bone Solutions Inc. (BSI), an orthobiologics technology ... device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with bone repair ... critical property for bone health and development. , “We’re excited to bring this ...
(Date:9/19/2017)... , ... September 19, 2017 , ... Premiere Long Island ... Sami, was recently named one of the best dentists in America under age 40 ... dental professionals nationwide. Every fall, the magazine features the best 40 dentists under the ...
(Date:9/19/2017)... ... September 19, 2017 , ... Inc. magazine ranked ... ranking of the nation's fastest-growing private companies. The list represents a unique look ... independent small and midsized businesses. Endo-Systems is a leading B2B distributor of today’s ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)...   OrthoAtlanta has been named the official orthopedic ... (AFHC) for the 2018 College Football Playoff (CFP) National Championship ... Stadium in Atlanta, Georgia . OrthoAtlanta is ... campaign, participating in many activities leading up to, and including ... ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
Breaking Medicine Technology: